Regenxbio

REGENXBIO INC

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Inc

Press Releases

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Earnings

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Small Cap

REGENXBIO Announces Presentation at the World Muscle Society

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

RGNX

Absci

Akebia Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

CytomX Therapeutics

Emergent BioSolutions

Erasca

Gossamer Bio

Gyre Therapeutics

I-MAB

Inventiva S.A. - American Depository Shares

Inventiva

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Monopar Therapeutics

Myriad Genetics

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Savara

Tango Therapeutics

Tyra Biosciences

Verastem

HC Wainwright & Co.

Chardan Capital

RBC Capital

Barclays

Goldman Sachs

Comments

Regenxbio

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO